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Maturity onset diabetes of the young (MODY) is the most common form of monogenic diabetes mellitus that
constitutes 1-2 % of the cases of diabetes mellitus. MODY3 is caused by mutations in the hepatocyte nuclear fac-
tor 1α gene (HNF1A) which are the most frequent cause of MODY in Japan. Characteristics of MODY3 are pro-
gressive insulin secretion defects and high sensitivity to sulfonylureas. Recently, incretin-related drugs such as
GLP-1 receptor agonists and DPP-4 inhibitors are also indicated for the treatment of patients with MODY3. Here,
we report two cases of MODY3 patients on insulin therapy who were given dipeptidyl peptidase-4 (DPP-4) inhibi-
tors. Patient 1, a 38-year-old man carrying P291fsinsC mutation, showed a remarkable reduction in daily insulin
dose (16 units to 8 units) without worsening of glycemic control after the administration of a DPP-4 inhibitor. Meal
tolerance test (MTT) revealed improvement in insulin secretion and slight suppression of glucagon secretion. Pa-
tient 2, a 67-year-old woman, carrying L584S585fsinsTC showed improvement in glycemic control after the ad-
ministration of a DPP-4 inhibitor, although the total daily insulin dose did not change (22 units to 20 units). MTT
revealed the same tendency as observed in case 1. Reduction in daily insulin dose and improvement of insulin se-
cretion were more significant in MODY3 patients than in patients with type 2 diabetes. In conclusion, administra-
tion of DPP-4 inhibitors to MODY3 patients who are on insulin treatment may be effective in improving glycemic
control because of improved insulin secretion and suppression of glucagon secretion.
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Table　1　Clinical findings before administration of DPP-4 inhibitor
a: Case 1
<Urianalysis> <Blood cell count>
Protein  (－) WBC (/μl) 4,540 CK (U/l) 70
Sugar  (－) Hb (g/dl) 15.9 AMY (U/l) 77
Ketone  (－) Ht (%) 46.0 BUN (mg/dl) 16.2
Plt (×103/μl) 27.3 Cr (mg/dl) 0.67
<Diabetic examination> eGFR 106.7
FBS (mg/dl) 112 <Serum chemistry> UA (mg/dl) 4.8
HbA1c (%)  6.2 Alb (g/dl) 4.7 T-chol (mg/dl) 191
ACR (mg/g・Cr)  2.2 T-bil (mg/dl) 0.7 HDL-C (mg/dl) 73
Retinopathy none AST (U/l) 15 TG (mg/dl) 39
GAD-Ab  (－) ALT (U/l) 6 LDL-C (mg/dl) 118
IA-2-Ab  (－) LD (U/l) 132 Na (mEq/l) 138
ALP (U/l) 170 K (mEq/l) 5.3




<Urianalysis> <Blood cell count>
Protein  (－) WBC (/μl) 9,590 CK (U/l) 79
Sugar  (－) Hb (g/dl) 12.7 AMY (U/l) Not tested
Ketone  (－) Ht (%) 37.0 BUN (mg/dl) 17.4
Plt (×103/μl) 18.8 Cr (mg/dl) 0.67
<Diabetic examination> eGFR 66.3
FBS (mg/dl) 112 <Serum chemistry> UA (mg/dl) 4.2
HbA1c (%)  6.6 Alb (g/dl) 3.7 T-chol (mg/dl) Not tested
ACR (mg/g・Cr)  2.2 T-bil (mg/dl) Not tested HDL-C (mg/dl) 61
Retinopathy Fukuda A1/A1 AST (U/l) 19 TG (mg/dl) 64
GAD-Ab  (－) ALT (U/l) 22 LDL-C (mg/dl) 152
IA-2-Ab Not tested LD (U/l) 182 Na (mEq/l) 146
ALP (U/l) Not tested K (mEq/l) 4.5


























初診時 BMI 18.6 kg/m2，空腹時血糖 249 mg/dl，
HbA1c（JDS）10.6 %より糖尿病と診断された．イン
スリン 2回法（朝食前ペンフィル NⓇ 8単位，夕食前
ペンフィル 30RⓇ 4単位）による治療を開始され，血







Fig.　1　Changes of HbA1c and daily insulin doses before and after administration of DPP-
4 inhibitor
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Fig.　2　Transition of each parameter in MTT before and after administration of DPP-4 
inhibitor
a and d, plasma glucose; b and e, CPR; c and f, glucagon. 
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Case 1 Case 2
関する報告１４）によれば，開始前後で BMIと 1日イン
スリン量には有意な変化を認めず，HbA1c（NGSP）
















Table　2　Comparison of MODY3 cases and T2DM patients
MODY3
T2DM＊
Case 1 Case 2
Age at diagnosis (years old) 15 49
Duration of diabetes (years) 22 18 19.9
Current age (years old) 38 67 59.4
Dose of Sitagliptin (mg) 25 25   50
Changes in before and after administration of Sitagliptin
BMI (kg/m2) 23.9 ⇒ 23.6 22.4 ⇒ 22.5 25.6 ⇒ 25.5
HbA1c (%) 6.2 ⇒ 6.3 6.6 ⇒ 6.6 8.3 ⇒ 7.6
Daily insulin dose (u/kg) 0.24 ⇒ 0.14
 (－0.10 u/kg) 
0.41 ⇒ 0.37
 (－0.04 u/kg) 
0.53 ⇒ 0.52
 (－0.01 u/kg) 












＊ 29 patients with T2DM under insulin therapy (Nakagami T et al12) ) .
＊＊ ∑ (pre, 120 min) in Case 1, ∑ (pre, 60 min, 120 min) in Case 2 and in T2DM patients.
＊＊＊ Measurement of glucagon was performed by Glucagon RIA kit (SML) for Case 1 and 2, Glucagon RIA 
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